Key facts
- It has raised $560K; the latest was Early Stage VC ($70K) in May 2025.
- Notable investors include US National Science Foundation, Launch Tennessee, MassBio, BioTN Foundation, Eli Lilly — 11 tracked in total.
- Orion Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Sep 2024 ($85K sold to 4 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Orion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Orion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orion Therapeutics
Operator of a biotechnology company intended to focus on early-stage ribonucleic acid therapy and vaccine development programs. The company supports the partners in the advancement of nucleic acid therapeutics and vaccines by providing formulation, analysis and preclinical proof-of-concept studies, enabling clients to increase the value of their nucleic acid assets by providing access to novel delivery systems.
- Sector
- Healthcare
- HQ
- Knoxville, TN, United States
- Founded
- 2022
- Employees
- 8
- Website
- orionthx.com/
- Ownership
- Privately Held (backing)
Orion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.